Neurology/psychiatric - Articles - Page 283

Newco news

Enveric Biosciences gears up for phase I anxiety trial with psilocin prodrug

June 27, 2023

Enveric Biosciences Inc. is gearing up to begin clinical trials in generalized anxiety disorder with lead candidate, EB-373, a psilocin prodrug. Trials are expected to begin in the fourth quarter of 2023.

Carthera raises €37.5M for ultrasound brain cancer device

June 27, 2023

By Shani Alexander

Carthera SA raised €37.5 million (US$40 million) in a series B funding round that will allow the company to embark on the first pivotal trial of its Sonocloud technology. The Sonocloud-9 is the only implantable ultrasound device that can repeatedly open the blood-brain barrier and deliver effective treatment in patients with recurrent glioblastoma, Frédéric Sottilini, CEO of Carthera, told BioWorld.

Neurology/Psychiatric

Astrazeneca divulges new RIPK1 inhibitors for neurological disorders

June 27, 2023

Astrazeneca AB has synthesized pyraolo-and triazolo-azinone compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of neurological disorders.

Side view of head and neck, highlighting the throat

Neurology/Psychiatric

Benitec’s BB-301 cleared to enter clinic in US for oculopharyngeal muscular dystrophy-related dysphagia

June 27, 2023

Benitec Biopharma Inc. has received FDA clearance of its IND application for BB-301, its silence and replace gene therapy for the treatment of oculopharyngeal muscular dystrophy (OPMD)-related dysphagia.

Neurology/Psychiatric

Convelo and Genentech patent new EBP inhibitors

June 26, 2023

Convelo Therapeutics Inc. and Genentech Inc. have disclosed 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Neurology/Psychiatric

French researchers describe new MAPT aggregation inhibitors for Alzheimer’s disease

June 23, 2023

Researchers at Centre National de la Recherche Scientifique, Université De Picardie Jules Verne and Université Paris-Est Créteil Val de Marne (UPEC) have identified lipid anionic oligosaccharides acting as microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.

Neurology/Psychiatric

University of Western Australia patents new MDMA analogues for modulating SERT, DAT and/or NET activity

June 23, 2023

University of Western Australia has disclosed 3,4-methylenedioxymethamphetamine (MDMA) analogues acting as dopamine transporter (DAT) and/or norepinephrine transporter (NET) and/or serotonin transporter (SERT) modulators reported to be useful for the treatment of neurological and psychiatric disorders.

Neurology/Psychiatric

Alchemab Therapeutics presents newly discovered CD33-targeting antibody for Alzheimer’s disease

June 23, 2023

Alchemab Therapeutics Ltd. has presented ATLX-1088, its newly discovered preclinical Alzheimer’s candidate, and provided early data.

Newco news

Enveric Biosciences gears up for phase I anxiety trial with psilocin prodrug

June 22, 2023

By Tamra Sami

Enveric Biosciences Inc. is gearing up to begin clinical trials in generalized anxiety disorder with lead candidate, EB-373, a psilocin prodrug. Trials are expected to begin in the fourth quarter of 2023.

Neurology/Psychiatric

Remix Therapeutics patents new RNA splicing modulators

June 22, 2023

Remix Therapeutics has disclosed compounds acting as RNA splicing modulators reported to be useful for the treatment of cancer and Huntington’s disease.